MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$3.31 USD
-0.34 (-9.32%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $3.31 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Income Statements
Fiscal Year end for MEI Pharma, Inc falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | |
---|---|---|---|---|---|
Sales | NA | 49 | 41 | 26 | 29 |
Cost Of Goods | NA | 0 | 0 | 1 | 3 |
Gross Profit | NA | 49 | 41 | 24 | 26 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 86 | 116 | 94 | 51 |
Income After Depreciation & Amortization | 0 | -37 | -75 | -70 | -25 |
Non-Operating Income | NA | 5 | 21 | 19 | -21 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -32 | -54 | -51 | -46 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -32 | -54 | -51 | -46 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -32 | -54 | -51 | -46 |
Depreciation Footnote | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -36 | -75 | -69 | -24 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -37 | -75 | -70 | -25 |
Earnings Per Share Data | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Average Shares | NA | 6.66 | 6.26 | 5.72 | 4.55 |
Diluted EPS Before Non-Recurring Items | NA | -5.02 | -13.40 | -16.80 | -5.20 |
Diluted Net EPS (GAAP) | NA | -4.78 | -10.00 | -13.60 | -10.20 |
Fiscal Year end for MEI Pharma, Inc falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 65.30 | 1.46 |
Cost Of Goods | NA | 0.00 | 3.91 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | -3.91 | 65.30 | 1.46 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 9.83 | 8.02 | 10.02 | 12.54 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -9.83 | -11.93 | 55.28 | -11.08 |
Non-Operating Income | NA | 0.70 | 0.87 | 1.09 | 1.05 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -9.13 | -11.06 | 56.37 | -10.03 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -9.13 | -11.06 | 56.37 | -10.03 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -9.13 | -11.06 | 56.37 | -10.03 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 6.66 | 6.66 | 6.66 | 6.66 |
Diluted EPS Before Non-Recurring Items | NA | -1.37 | -1.66 | 8.46 | -1.51 |
Diluted Net EPS (GAAP) | NA | -1.37 | -1.66 | 8.46 | -1.66 |